Beam Therapeutics announced that updated Phase 1/2 BEAM-302 data will be presented in a late-breaking oral session at the European Respiratory Society Congress on September 8, 2026. The July 23 announcement is a catalyst…
A binding arbitration tribunal ruled that PM647, Prime Medicine’s investigational prime-editing therapy for Alpha-1 Antitrypsin Deficiency, falls within Prime Medicine’s contractual ‘Field’ as defined under the parties’ 2019 Collaboration and License Agreement with Beam…
Beam Therapeutics presented updated Phase 1/2 data for BEAM-302 at ATS 2026, reinforcing the company’s in vivo base-editing platform and supporting plans for an accelerated approval strategy in Alpha-1 Antitrypsin Deficiency (AATD).
Beam Therapeutics announced updated biomarker data from the Phase 1/2 BEACON trial of ristoglogene autogetemcel (risto-cel), reinforcing its position as the leading base-edited cell therapy program in sickle cell disease ahead of a planned…
